Clinical Trial Pipeline for MASH 2026
Nov
2026
Description
This session on the MASH clinical trial pipeline explores the rapid evolution of drug development. It covers emerging molecules in the pipeline, mechanisms of action, and late-stage trial endpoints addressing fibrosis and cirrhosis.
Presentations
11:00 AM
- 11:15 AM
Convention Center - Bluebird Ballroom 1A
Efruxifermin Drives Multidimensional Histologic Improvement in Compensated Cirrhosis: An AI-Based Analysis from the SYMMETRY Randomized Controlled Trial
Mazen Noureddin, MD, , MHSc, FAASLD | Abstract Presenter
11:15 AM
- 11:30 AM
Convention Center - Bluebird Ballroom 1A
Stage-Stratified Comparative Effectiveness of Tirzepatide Versus SGLT2 Inhibitors in Type 2 Diabetes (T2DM) on major adverse liver outcomes (MALO) and major adverse cardiovascular events (MACE) With MASLD/MASH
Mohammad Alabbas, M.D | Abstract Presenter
11:30 AM
- 11:45 AM
Convention Center - Bluebird Ballroom 1A
Pemvidutide Treatment Results in Concurrent Reductions in Multiple Non-Invasive Tests for Hepatic Inflammation and Fibrosis: 48-Week Responder Analyses of the IMPACT Phase 2b Trial in Metabolic Dysfunction-Associated Steatohepatitis
Naim Alkhouri | Abstract Presenter
11:45 AM
- 12:00 PM
Convention Center - Bluebird Ballroom 1A
Liver-Directed RNA Interference Targeting Cell Death-Inducing DFFA-Like Effector B (CIDEB) Normalizes Liver Fat and Lowers Serum Transaminase Levels in Metabolic Dysfunction-Associated Liver Disease (MASLD)
Jorg Taubel | Abstract Presenter
12:00 PM
- 12:15 PM
Convention Center - Bluebird Ballroom 1A
Clinically Silent Advanced Liver Fibrosis in U.S. Adults With Normal Aminotransferases: AnExplainable Artificial Intelligence Analysis of NHANES 2017–2018
Nayanika Tummala, MD | Abstract Presenter
12:15 PM
- 12:30 PM
Convention Center - Bluebird Ballroom 1A
HRS-4729, a novel GLP-1/GIP/Glucagon triple-receptor agonist, reduces liver fat in participants living with metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity: a randomized, double-blind, placebo-controlled phase 1b
Mengshan Ni, PhD | Abstract Presenter
